



**19 September 2019**

ASX Announcement / Media Release

## Director Appointment-Clarification

---

**19 September 2019** – On 17 September 2019, Race Oncology Limited (ASX: RAC) (the Company) announced the appointment of Dr Daniel Tillett as a Director. The Company wishes to clarify that Dr Tillett has been appointed as a non-executive Director.

- ENDS -

### **About Race Oncology (RAC: ASX)**

Race Oncology is a specialty pharmaceutical company whose business model is to pursue later-stage drug assets in the cancer field that have been overlooked by big pharma. The company's first asset is Bisantrene, a chemotherapy drug, which was the subject of more than 40 clinical studies during the 1980s and 1990s before the drug was abandoned. Bisantrene has compelling Phase II data in acute myeloid leukaemia (AML) and Race is seeking to gain US FDA approval for Bisantrene for AML under the accelerated 505(b)(2) regulatory pathway. Bisantrene is the subject of two recently granted US patents and a third allowed US patent. It has also been awarded US Orphan Drug designation and a 'Rare Paediatric Disease' (RPD) designation.

### Media contact:

Heidi Cuthbert

+61 411 272 366

E: [heidi.cuthbert@multiplier.com.au](mailto:heidi.cuthbert@multiplier.com.au)